Biogen Inc. (NASDAQ:BIIB) on Tuesday entered into an agreement with Alloy Therapeutics Inc. to accelerate the development of antisense therapies targeting multiple undisclosed indications.

Waltham, Massachusetts-based Alloy will receive an upfront payment and stands to earn additional milestone-based compensation, along with tiered royalties on any commercialized products arising from the partnership.

Expanding RNA-Targeted Drug Development

Alloy’s AntiClastic ASO platform is designed to improve the effectiveness of antisense therapeutics by enabling drug developers to target disease pathways at the RNA level within cells.

The approach seeks to address longstanding challenges in the field, particularly around drug potency and therapeutic index.

Historically, antisense drugs have faced limitations due to poor biodistribution, which has constrained their clinical efficacy.

Alloy's Broader ...